3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Status
Active not recruiting
2
Completed
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
2
Tumor-Agnostic
1
Conditions
Carcinoma, Non-Small-Cell Lung
16
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Small Cell Lung Carcinoma
3
Carcinoma
3
Urothelial Cancer
2
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Endometrial Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Recurrence
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
1
Non Small Cell Lung Cancer NSCLC
1
Neurocytoma
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Metastatic Urothelial Cancer
1
Mesothelioma
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Ganglioneuroma
1
Ganglioglioma
1
Interventions
Pemetrexed
3
Carboplatin
3
durvalumab
2
Cisplatin
2
tremelimumab
1
repotrectinib
1
pralsetinib
1
osimertinib
1
brigatinib
1
atezolizumab
1
Surgical Procedures, Operative
1
Paclitaxel
1
Mitomycin
1
Gemcitabine
1
Crizotinib
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Has announcements
×
Carcinoma
×
Carboplatin
×
Clear all
NCT04035486
2025-10-10
FLAURA2
AstraZeneca
Phase 3
Active not recruiting
587 enrolled
44 charts
1 FDA
NCT03800134
2025-06-11
AEGEAN
AstraZeneca
Phase 3
Active not recruiting
825 enrolled
1 FDA
NCT02367781
2021-08-09
IMpower130
Hoffmann-La Roche
Phase 3
Completed
723 enrolled
28 charts
1 FDA